MX371095B - Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. - Google Patents

Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.

Info

Publication number
MX371095B
MX371095B MX2015014329A MX2015014329A MX371095B MX 371095 B MX371095 B MX 371095B MX 2015014329 A MX2015014329 A MX 2015014329A MX 2015014329 A MX2015014329 A MX 2015014329A MX 371095 B MX371095 B MX 371095B
Authority
MX
Mexico
Prior art keywords
methods
metap2 inhibitors
modified
treating obesity
relates
Prior art date
Application number
MX2015014329A
Other languages
English (en)
Other versions
MX2015014329A (es
Inventor
John S Petersen
James Shanahan
Original Assignee
Syndevrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndevrx Inc filed Critical Syndevrx Inc
Publication of MX2015014329A publication Critical patent/MX2015014329A/es
Publication of MX371095B publication Critical patent/MX371095B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a inhibidores de MetAP2 modificados o conjugados con polímero; la presente invención también se refiere a métodos para evitar, inducir, causar o incrementar la pérdida de peso, tratar la obesidad y/o tratar el síndrome metabólico utilizando los inhibidores de MetAP2 modificados o conjugados con polímero; la presente invención también se refiere a métodos de mejorar la sensibilidad a la insulina y el control glucémico, reduciendo los niveles de insulina y/o mejorando la sensibilidad a la leptina utilizando los inhibidores de MetAP2 modificados o conjugados con polímero.
MX2015014329A 2013-04-10 2014-04-09 Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. MX371095B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810468P 2013-04-10 2013-04-10
US201461925918P 2014-01-10 2014-01-10
PCT/US2014/033476 WO2014169026A1 (en) 2013-04-10 2014-04-09 Metap2 inhibitors and methods of treating obesity

Publications (2)

Publication Number Publication Date
MX2015014329A MX2015014329A (es) 2016-06-21
MX371095B true MX371095B (es) 2020-01-16

Family

ID=51686946

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014329A MX371095B (es) 2013-04-10 2014-04-09 Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.

Country Status (13)

Country Link
US (8) US9173956B2 (es)
EP (2) EP3574922B1 (es)
JP (4) JP6420314B2 (es)
CN (2) CN105431426A (es)
AU (1) AU2014250983B2 (es)
BR (1) BR112015025892A2 (es)
CA (1) CA2908993C (es)
DK (2) DK2984085T3 (es)
EA (1) EA033912B1 (es)
ES (2) ES2749746T3 (es)
HK (1) HK1216313A1 (es)
MX (1) MX371095B (es)
WO (1) WO2014169026A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
DK2576638T3 (da) * 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
MX371095B (es) * 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
CN106432255A (zh) * 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
ES2893749T3 (es) * 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
WO2017123603A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
CN114573476B (zh) * 2020-09-14 2024-06-11 广州药本君安医药科技股份有限公司 线性头尾二胺桥连化合物及在制备治疗糖代谢紊乱疾病药物中的应用
WO2023156996A1 (en) * 2022-02-16 2023-08-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metap2 inhibitors and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US20020076442A1 (en) * 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
US6835807B1 (en) 1998-05-22 2004-12-28 Daiichi Pharmaceuticals Co., Ltd. Drug complex and drug delivery system
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
US6811996B1 (en) 1998-10-30 2004-11-02 Daiichi Pharmaceutical Co., Ltd. DDS compounds and method for assaying the same
AU7025600A (en) 1999-09-08 2001-04-10 School Of Pharmacy, University Of London, The Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US20070161570A1 (en) * 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
DE60233420D1 (de) 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
EP1483579A4 (en) 2002-02-15 2006-07-12 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION AND USE OF CONJUGATES, FORMULATION AND PHARMACEUTICAL APPLICATIONS OBTAINED FROM SUCH CONJUGATES
JP4514455B2 (ja) 2002-04-11 2010-07-28 チルドレンズ メディカル センター コーポレーション Ｔｎｐ−４７０ポリマー複合体及びその使用
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
US7700280B2 (en) 2003-12-31 2010-04-20 The Penn State Research Foundation Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
CN101142210A (zh) * 2005-01-26 2008-03-12 株式会社钟根堂 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物
WO2006084054A2 (en) 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
NZ585547A (en) 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
EP2307032A4 (en) 2008-05-22 2014-08-20 Univ Ramot NOVEL POLYMER CONJUGATES HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS-TARGETING FRACTION AND USES THEREOF FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital INHIBITION OF NOTCH FOR THE TREATMENT AND PREVENTION OF OBESITY AND METABOLIC SYNDROME
US20130266578A1 (en) * 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
DK2576638T3 (da) 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
US20110294952A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized Drug Conjugates
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
KR101892768B1 (ko) 2010-11-09 2018-08-28 자프겐 인크. Metap-2 저해제의 결정질 고체 및 그의 제조 및 이용 방법
EP2646016B1 (en) * 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
KR101875988B1 (ko) * 2011-03-08 2018-07-06 자프겐 인크. 옥사스피로[2.5]옥탄 유도체 및 유사체
MX371095B (es) 2013-04-10 2020-01-16 Syndevrx Inc Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
ES2893749T3 (es) 2015-12-10 2022-02-10 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos
WO2017123603A1 (en) 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction

Also Published As

Publication number Publication date
HK1216313A1 (zh) 2016-11-04
US20140308235A1 (en) 2014-10-16
JP2023082195A (ja) 2023-06-13
US20150374657A1 (en) 2015-12-31
US20180271856A1 (en) 2018-09-27
CA2908993A1 (en) 2014-10-16
ES2902082T3 (es) 2022-03-24
AU2014250983B2 (en) 2019-04-11
US9757373B2 (en) 2017-09-12
ES2749746T3 (es) 2020-03-23
US20170028014A1 (en) 2017-02-02
US20230048989A1 (en) 2023-02-16
JP2019023219A (ja) 2019-02-14
US11304944B2 (en) 2022-04-19
EP3574922B1 (en) 2021-09-15
JP2021091738A (ja) 2021-06-17
EP3574922A1 (en) 2019-12-04
US9750737B2 (en) 2017-09-05
CA2908993C (en) 2023-05-23
DK3574922T3 (da) 2021-12-06
US20200155545A1 (en) 2020-05-21
US10588904B2 (en) 2020-03-17
JP6420314B2 (ja) 2018-11-07
US10010544B2 (en) 2018-07-03
EA033912B1 (ru) 2019-12-09
CN105431426A (zh) 2016-03-23
EP2984085B1 (en) 2019-07-17
EP2984085A1 (en) 2016-02-17
CN112494476A (zh) 2021-03-16
US20160346244A1 (en) 2016-12-01
US20170326135A1 (en) 2017-11-16
WO2014169026A1 (en) 2014-10-16
MX2015014329A (es) 2016-06-21
EP2984085A4 (en) 2016-12-07
US9433600B2 (en) 2016-09-06
DK2984085T3 (da) 2019-10-21
EA201591943A1 (ru) 2016-07-29
BR112015025892A2 (pt) 2017-07-25
US9173956B2 (en) 2015-11-03
AU2014250983A1 (en) 2015-10-29
JP2016519106A (ja) 2016-06-30

Similar Documents

Publication Publication Date Title
MX371095B (es) Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad.
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX369921B (es) Tratamiento de la hgna y ehna.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MY181888A (en) Tmprss6 irna compositions and methods of use thereof
MY169328A (en) Compositions for the treatment of dry eye
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CL2012002217A1 (es) Polipeptido aislado que comprende cuando menos un monómero de un solo dominio variable de un agente nb que se enlaza a dr5 humano; metodo para la prevencion y/o el tratamiento de un trastorno que se puede tratar mediante la mejora de la apoptosis celular.
MX2016008096A (es) Tratamiento de superficies de particulas y uso de las mismas.
EP3164125A4 (en) Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes
EP3065768A4 (en) Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
BR112016012248A2 (pt) método de tratamento de nefropatia
MX2016010229A (es) Conjugados del factor vii.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
PH12017500084A1 (en) Vitamin b2 and its use
EA201992065A3 (ru) ИНГИБИТОРЫ MetAP2 И СПОСОБЫ ЛЕЧЕНИЯ ОЖИРЕНИЯ
MX2017012231A (es) Secuencias de oligonucleotidos dirigidos al factor de transcripcion tsc22d4 para el tratamiento de la resistencia a la insulina.
WO2014205237A3 (en) Compositions and methods for use of high molecular weight hyaluronic acid for cancer therapy

Legal Events

Date Code Title Description
FG Grant or registration